Pfizer Advances Early PF-07328948 Liver Study, Adding Quiet Support to PFE’s Pipeline Story

Pfizer Inc (PFE) announced an update on their ongoing clinical study.

Pfizer Inc. (PFE) is running a Phase 1 study called “A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-COHORT STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF PF-07328948 IN ADULTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIRMENT.” The goal is to see how its experimental pill PF-07328948 is processed in adults with different levels of liver function, which helps guide dosing, safety, and future trial design.

The treatment is a single oral tablet of PF-07328948, given once in the clinic. It is an early‑stage drug aimed at understanding how the body absorbs and clears the medicine, especially when liver function is reduced.

The study uses a non‑randomized, parallel‑group design, so participants are placed into fixed cohorts based on their liver status rather than by chance. It is open‑label with no masking, and the main purpose is basic research on how the drug moves through the body rather than testing clinical benefit.

The trial is listed as recruiting, indicating active enrollment. The record was first submitted on November 25, 2025, and the most recent update on March 16, 2026, signals that details such as design or timelines have been refreshed for investors and regulators.

For investors, this update is a small but positive sign that Pfizer continues to invest in its early‑stage pipeline and in better dosing guidance for complex patients, such as those with liver disease. While a Phase 1 hepatic‑impairment study will not move PFE stock by itself, it adds incremental value to the asset’s risk profile and keeps Pfizer competitive versus large peers that highlight similar precision‑dosing data in their development programs.

The study remains active and updated, with more information available on the ClinicalTrials.gov portal.

To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.